280 related articles for article (PubMed ID: 33668244)
1. Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer.
How JA; Jazaeri AA; Fellman B; Daniels MS; Penn S; Solimeno C; Yuan Y; Schmeler K; Lanchbury JS; Timms K; Lu KH; Yates MS
Cancers (Basel); 2021 Feb; 13(5):. PubMed ID: 33668244
[TBL] [Abstract][Full Text] [Related]
2. Biomarker Assessment of Homologous Recombination Deficiency in Epithelial Ovarian Cancer: Association With Progression-Free Survival After Surgery.
Yi H; Li L; Huang J; Ma Z; Li H; Chen J; Zheng X; Chen J; He H; Song J
Front Mol Biosci; 2022; 9():906922. PubMed ID: 35769916
[TBL] [Abstract][Full Text] [Related]
3. Homologous Recombination Deficiency Assays in Epithelial Ovarian Cancer: Current Status and Future Direction.
Chiang YC; Lin PH; Cheng WF
Front Oncol; 2021; 11():675972. PubMed ID: 34722237
[TBL] [Abstract][Full Text] [Related]
4. A high homologous recombination deficiency score is associated with poor survival and a non-inflamed tumor microenvironment in head and neck squamous cell carcinoma patients.
Chen Y; Zheng X; Lin J; Gao X; Xiong J; Liu J; Fei Z; Chen C
Oral Oncol; 2022 May; 128():105860. PubMed ID: 35428026
[TBL] [Abstract][Full Text] [Related]
5. Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer types.
Budczies J; Kluck K; Beck S; Ourailidis I; Allgäuer M; Menzel M; Kazdal D; Perkhofer L; Kleger A; Schirmacher P; Seufferlein T; Stenzinger A
J Pathol Clin Res; 2022 Jul; 8(4):371-382. PubMed ID: 35384413
[TBL] [Abstract][Full Text] [Related]
6. Homologous Recombination Deficiency Score Determined by Genomic Instability in a Romanian Cohort.
Rădoi VE; Țurcan M; Maioru OV; Dan A; Bohîlțea LC; Dumitrescu EA; Gheorghe AS; Stănculeanu DL; Thodi G; Loukas YL; Săbău ID
Diagnostics (Basel); 2023 May; 13(11):. PubMed ID: 37296748
[TBL] [Abstract][Full Text] [Related]
7. Genomic Determinants of Homologous Recombination Deficiency across Human Cancers.
Qing T; Wang X; Jun T; Ding L; Pusztai L; Huang KL
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572800
[TBL] [Abstract][Full Text] [Related]
8. Homologous Recombination Deficiency Associated With Response to Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer Patients: The First Real-World Evidence From China.
Ni J; Guo W; Zhao Q; Cheng X; Xu X; Zhou R; Gu H; Chen C; Chen X
Front Oncol; 2021; 11():746571. PubMed ID: 35070965
[TBL] [Abstract][Full Text] [Related]
9. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
Liu FW; Tewari KS
Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
[TBL] [Abstract][Full Text] [Related]
10. Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy.
Sheta R; Bachvarova M; Plante M; Renaud MC; Sebastianelli A; Gregoire J; Navarro JM; Perez RB; Masson JY; Bachvarov D
J Transl Med; 2020 Nov; 18(1):439. PubMed ID: 33213473
[TBL] [Abstract][Full Text] [Related]
11. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
Timms KM; Abkevich V; Hughes E; Neff C; Reid J; Morris B; Kalva S; Potter J; Tran TV; Chen J; Iliev D; Sangale Z; Tikishvili E; Perry M; Zharkikh A; Gutin A; Lanchbury JS
Breast Cancer Res; 2014 Dec; 16(6):475. PubMed ID: 25475740
[TBL] [Abstract][Full Text] [Related]
12. Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of the literature.
Frey MK; Pothuri B
Gynecol Oncol Res Pract; 2017; 4():4. PubMed ID: 28250960
[TBL] [Abstract][Full Text] [Related]
13. Homologous recombination repair deficiency (HRD) testing in newly diagnosed advanced-stage epithelial ovarian cancer: A Belgian expert opinion.
Vergote I; Denys H; Altintas S; Kerger J; Baurain JF; Bours V; Henry S; Van de Vijver K; Lambrechts D; Gennigens C
Facts Views Vis Obgyn; 2022 Jun; 14(2):111-120. PubMed ID: 35781107
[TBL] [Abstract][Full Text] [Related]
14. A Functional Homologous Recombination Assay Predicts Primary Chemotherapy Response and Long-Term Survival in Ovarian Cancer Patients.
Tumiati M; Hietanen S; Hynninen J; Pietilä E; Färkkilä A; Kaipio K; Roering P; Huhtinen K; Alkodsi A; Li Y; Lehtonen R; Erkan EP; Tuominen MM; Lehti K; Hautaniemi SK; Vähärautio A; Grénman S; Carpén O; Kauppi L
Clin Cancer Res; 2018 Sep; 24(18):4482-4493. PubMed ID: 29858219
[No Abstract] [Full Text] [Related]
15. BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor.
Sahnane N; Carnevali I; Formenti G; Casarin J; Facchi S; Bombelli R; Di Lauro E; Memoli D; Salvati A; Rizzo F; Sessa F; Tibiletti MG
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352687
[TBL] [Abstract][Full Text] [Related]
16. A Benchmark of In-House Homologous Recombination Repair Deficiency Testing Solutions for High-Grade Serous Ovarian Cancer Diagnosis.
Guarischi-Sousa R; Kroll JE; Bonaldi A; Pierry PM; Villela D; Souza CA; Silva JS; Bürger MC; Oliveira FA; de Paula MG; Meliso FM; de Almeida LG; Monfredini PM; de Oliveira AG; Milanezi F; Scapulatempo-Neto C; Yamamoto GL
Diagnostics (Basel); 2023 Oct; 13(21):. PubMed ID: 37958189
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of homologous recombination deficiency score testing in endometrial Cancer.
Siedel JH; Ring KL; Hu W; Dood RL; Wang Y; Baggerly K; Darcy KM; Conrads TP; Gallagher S; Tshiaba P; Neff C; Timms KM; Mangala S; Westin SN; Broaddus R; Lopez-Berestein G; Lu KH; Coleman RL; Maxwell GL; Sood AK
Gynecol Oncol; 2021 Mar; 160(3):777-785. PubMed ID: 33563487
[TBL] [Abstract][Full Text] [Related]
18. Homologous Recombination Deficiency in Ovarian Cancer: from the Biological Rationale to Current Diagnostic Approaches.
Mangogna A; Munari G; Pepe F; Maffii E; Giampaolino P; Ricci G; Fassan M; Malapelle U; Biffi S
J Pers Med; 2023 Feb; 13(2):. PubMed ID: 36836518
[TBL] [Abstract][Full Text] [Related]
19. Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer.
Patel JN; Braicu I; Timms KM; Solimeno C; Tshiaba P; Reid J; Lanchbury JS; Darb-Esfahani S; Ganapathi MK; Sehouli J; Ganapathi RN
Br J Cancer; 2018 Oct; 119(9):1060-1066. PubMed ID: 30318511
[TBL] [Abstract][Full Text] [Related]
20. HRD effects on first-line adjuvant chemotherapy and PARPi maintenance therapy in Chinese ovarian cancer patients.
Li L; Gu Y; Zhang M; Shi X; Li Z; Xu X; Sun T; Dong Y; Xue C; Zhu X; Lv R; Jiao K; Ji X; Wang LJ; Zhang Y; Liang Z; Jin Y; Yin R; Wu M; Liang H
NPJ Precis Oncol; 2023 May; 7(1):51. PubMed ID: 37258600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
